Randomized Trialvery high evidence
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine·September 21, 2023·PMID 37622681
Why it mattersThis is the first targeted pharmacotherapy shown to improve symptoms, functional capacity, and weight loss specifically in obesity-related HFpEF, a phenotype with high unmet need and no approved therapies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled